Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

The Lancet COPD Commission: broader questions remain

Petousi N. et al, (2023), The Lancet, 401, 1569 - 1570

Dupilumab Improves Long-term Outcomes in Patients With Uncontrolled, Moderate-to-Severe GINA-Based Type 2 Asthma, Irrespective of Allergic Status.

Rabe KF. et al, (2023), Allergy

Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics

Busse WW. et al, (2023), Journal of Asthma and Allergy, Volume 16, 411 - 419

Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.

Agustí A. et al, (2023), Respirology

A randomised trial of a T2-composite-biomarker strategy adjusting corticosteroidtreatment in severe asthma, a post- hoc analysis by sex.

Eastwood MC. et al, (2023), J Allergy Clin Immunol Pract

Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of ICS dose

Pavord I. et al, (2022)

Baseline FeNO Independently Predicts the Dupilumab Response in Patients with Moderate-To-Severe Asthma.

Pavord ID. et al, (2022), J Allergy Clin Immunol Pract

Measurement of exhaled nitric oxide fails to predict left atrial pressure assessed by E/e ratio in elderly patients.

Jones ST. et al, (2022), BJGP Open

Asthma remission: what is it and how can it be achieved?

Thomas D. et al, (2022), Eur Respir J, 60

Diagnosis and assessment of the asthmas.

Pavord ID. et al, (2022), J Allergy Clin Immunol Pract

Case-finding and diagnosis of obstructive airway diseases: the Dragons' Den experience.

Pavord ID., (2022), Eur Respir J, 60

Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy

Chen S. et al, (2022), International Journal of Chronic Obstructive Pulmonary Disease, Volume 17, 2187 - 2200

Treatable traits in the NOVELTY study.

Agustí A. et al, (2022), Respirology

Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation.

Diver S. et al, (2022), Allergy

Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing

Couillard S. et al, (2022), Thorax

Exacerbation Profile and Risk Factors in a T2-Low Severe Asthma Population.

McDowell PJ. et al, (2022), Am J Respir Crit Care Med

Sub-stratification of type-2 high airway disease for therapeutic decision-making: a ‘bomb' (blood eosinophils) meets ‘magnet' (FeNO) framework

Couillard Castonguay S. et al, (2022), Respirology

Airway remodelling rather than cellular infiltration characterises both type2 cytokine biomarker-high and -low severe asthma

Khalfaoui L. et al, (2022), Allergy

Blood eosinophils, fractional exhaled nitric oxide, and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling

Couillard Castonguay S. et al, (2022), BMJ Open

Perspectives of mild asthma patients on maintenance versus as-needed preventer treatment regimens: a qualitative study.

Foster J. et al, (2022), BMJ Open, 12

Load More

Include forthcoming?